People news: Cephalon and PhRMA

Share this article:
Cephalon named J. Kevin Buchi CEO and a member of the company's board of directors. Buchi, who was previously COO and CFO at the company and has led business development for the past seven years, replaces founder Frank Baldino in that role. Baldino died last week at age 57. Cephalon said the board will address the role of chairman in the future, and William Egan will continue to serve as the company's independent presiding director.

PhRMA named four new members to its board of directors, including: Ian Read, Pfizer's president and CEO; Jerzy Gruhn, president of Novo Nordisk in the US; Mark Iwicki, president and COO of Sunovion Pharmaceuticals, and Staffan Schuberg, president of Lundbeck's US unit.  
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.